SCHEMBL18354431

SCHEMBL18354431

c1ccc(CCNc2nc(-c3cccnc3)nc3ccccc23)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 14/20 1.00
PDE5A O76074 6/20 0.75
ALDH1A1 P00352 3/20 0.69
LMNA P02545 2/20 0.69
HPGD P15428 1/20 0.69
CYP1A2 P05177 2/20 0.64
CYP3A4 P08684 2/20 0.64
CYP2D6 P10635 2/20 0.64
TSHR P16473 2/20 0.64
MAPK1 P28482 2/20 0.64
CYP2C19 P33261 2/20 0.64
HSD17B10 Q99714 2/20 0.64
CLK4 Q9HAZ1 2/20 0.64
MEN1 O00255 1/20 0.64
USP2 O75604 1/20 0.64
TP53 P04637 1/20 0.64
PTGS1 P23219 1/20 0.64
TBXAS1 P24557 1/20 0.64
PTGS2 P35354 1/20 0.64
KMT2A Q03164 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064493 0.91 GBA1 (0.82) GBA1PDE5AALDH1A1MAPK1MEN1
SCHEMBL16183653 0.87 GBA1 (0.77) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL16183659 0.87 GBA1 (0.77) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL22201478 0.87 GBA1 (0.77) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL7278036 0.86 GBA1 (1.00) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL16183656 0.86 GBA1 (0.74) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL16183660 0.86 GBA1 (0.74) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL18354079 0.85 GBA1 (1.00) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL16183654 0.84 GBA1 (0.72) GBA1PDE5AALDH1A1LMNAHPGD
SCHEMBL16183655 0.83 GBA1 (0.71) GBA1PDE5AALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934270-B2 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity NORTHWESTERN UNIVERSITY (US) 2021-03-02 US disclosed
US-20200071292-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY NORTHWESTERN UNIVERSITY (US) 2020-03-05 US disclosed
US-10167270-B2 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity NORTHWESTERN UNIVERSITY (US) 2019-01-01 US disclosed
US-20170001976-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY NORTHWESTERN UNIVERSITY (US) 2017-01-05 US disclosed
US-20170001976-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY NORTHWESTERN UNIVERSITY (US) 2017-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934270-B2 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity GBA1, GAA, GBA2 GBA1 1/4885PDE5A 641/4885ALDH1A1 2347/4885
US-20200071292-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY GBA1, GAA, GBA2 GBA1 1/4885PDE5A 641/4885ALDH1A1 2347/4885
US-20170001976-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY GBA1, GAA, GBA2 GBA1 1/4885PDE5A 641/4885ALDH1A1 2347/4885
US-10167270-B2 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity GBA1, GAA, GBA2 GBA1 1/4885PDE5A 641/4885ALDH1A1 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.